Founder of Trust Bio-sonics
Chung-Hsin Wang enrolled at Tsinghua University to study for a doctorate degree in medical ultrasound development and research in 2009. In 2012, he won the national innovation award from the Institute for Biotechnology and Medicine Industry for his ultrasound imaging contrast agent platform and obtained his doctorate. In 2013, he founded Trust Bio-sonics, which is committed to developing ultrasound contrast agents for laboratory animals and completed the product prototype in September the same year. In 2014, he was selected as a member of SVT Immersion Program and went to Silicon Valley to learn from several renowned angel investors. The following year, he completed product development, and the product was selected as an IDX by the Center for Drug Evaluation, Taiwan. In 2016, the product was patented in Taiwan and in a number of other countries including Japan and the US, and its pre-clinical effect was verified several times. The company also established a partnership with the National Taiwan University Hospital, the Mackay Memorial Hospital, University of California, San Diego and other medical centres. At the beginning of 2017, the company obtained investment of NTD120 million from institutional investors including several well-known venture capitals and pharmaceutical factories and the National Development Fund. At the end of the same year, it confirmed the clinical development strategy of the product upon consultation with the FDA. The product was expected to be clinically tested in humans in 2018.